Early Stage Strategy EU Pharmaceuticals

What an early stage EU strategy should include

1. Regulatory pathway alignment

The first question is not simply whether your product can enter Europe. It is how to structure the most credible, efficient, and scalable path. Within the EU regulatory strategy, the ‘first pillar’ serves as the foundation for patient-centric approaches and for boosting research and innovation ecosystems, making it essential to align early-stage planning with these priorities.

This includes:

• identifying the optimal development and approval route
• aligning nonclinical, CMC, and clinical packages with EU expectations
• anticipating classification or borderline-product questions where relevant
• preparing for accelerated review expectations and evidence-readiness needs

Recent updates to EU pharmaceutical legislation include the adoption of a new regulation and a new directive, with directives playing a key role in shaping the regulatory framework for pharmaceuticals, digital interoperability, and patient safety across the EU.

The latest EU reforms point to shorter centralized assessment timelines and a broader push toward regulatory efficiency, which increases the value of submission-ready planning much earlier in development.

In light of the European Commission’s proposal for regulatory reform, it is important to note that the Centralized Procedure is the most common pathway for innovative therapies, providing a single marketing authorization valid across all 27 EU Member States. Navigating the EU’s 27 member states requires an early selection of the most efficient Marketing Authorization pathway.

2. Clinical development strategy for Europe

Your clinical plan should not be copied from a US-first model without adjustment. Europe may require different assumptions around sites, endpoints, patient populations, comparator strategy, and evidence sequencing. Aligning clinical development with the needs of health systems is essential to ensure effective adoption of new technologies and to address sector-specific challenges.

A strong early-stage European strategy helps teams answer:

• Should Europe be included in the first clinical expansion wave?
• Which countries are best suited for early trial activation?
• How should protocol design support future EU regulatory and access discussions?
• What evidence gaps could slow approval or reimbursement later?
• Are Target Product Profiles defining clinical benefits and differentiators early enough to meet both regulatory standards and payer needs?

In addition, enhancing the European research and innovation ecosystem is crucial, with investments in research infrastructure and collaborative initiatives. From 2025, the Joint Clinical Assessment (JCA) framework will require that submitted data align with the PICO (Patient, Intervention, Comparator, Outcomes) framework, making early planning and data structuring essential.

Early planning becomes even more important when review windows are compressed and evidence packages need to mature faster.

Biotech clusters in countries like France, Spain or Germany play a key role by providing access to clinical validation infrastructure and public-private funding, supporting early-stage strategy for EU pharmaceuticals.

3. Exclusivity and asset value planning

Europe’s evolving data-protection and market-protection framework should influence development strategy, indication prioritization, and lifecycle planning. The 2026 reforms keep the standard data protection period at eight years while changing the standard market protection period and allowing extensions in specific cases. Orphan products also face a revised exclusivity structure.

Specialized regulations for rare diseases and paediatric regulation ( PIP) are increasingly important, as EU legislative reforms aim to improve access, incentivize innovation, and ensure safety and efficacy for pediatric and rare disease populations.

For innovators, this means early strategic choices matter, including:

• indication sequencing
• unmet-need positioning
• orphan strategy
• pediatric planning
• evidence generation to support differentiation

The EU is placing greater emphasis on incentivizing the development of therapies that address unmet medical needs, including critical areas such as antimicrobial resistance, through legislative objectives and regulatory incentives. Value-based pricing models are also shifting from traditional cost-plus approaches to assess rewards based on patient outcomes and the ability to address unmet medical needs.

It is essential to address the Pediatric Investigation Plan (PIP), a mandatory requirement in the EU that can delay approval if not planned early. The reform framework also modifies the data protection period from a flat rate to a baseline of 8 years, with possible extensions based on specific conditions.

A well-designed EU strategy protects more than compliance. It supports valuation, partnering, and long-term competitive positioning.

4. Supply, manufacturing, and operational readiness

European expansion increasingly requires early thought about continuity of supply, manufacturing setup, and operational resilience. The new framework strengthens obligations related to shortages, notifications, and continuity planning, including expectations for shortage prevention and attention to critical medicines. New EU rules now require manufacturers to develop shortage prevention plans and notify authorities of potential supply disruptions earlier.

That is why early strategy should cover:

• supply chain design for European launch and scale-up
• country sequencing based on operational feasibility
• manufacturing and release considerations
• risk mitigation for future shortages or disruptions

In particular, planning must ensure the availability of essential medicines and address systemic shortages by identifying vulnerabilities and implementing measures to prevent and manage systemic shortages across the EU. The EU’s pharmaceutical supply chain is heavily exposed to geographical, environmental, and political troubles due to reliance on non-EU countries for critical active pharmaceutical ingredients (APIs), which increases the risk of disruptions and highlights the need for greater resilience.

This is especially important for advanced, specialized, or personalized therapies where distribution and manufacturing models are part of the strategy, not just execution.

Early stage strategy for EU pharmaceuticals should also prioritize crisis preparedness and security, emphasizing the importance of robust production capabilities within Europe to support a resilient supply chain. Ensuring a strong EU voice in global pharmaceutical supply chains is crucial to improve resilience, competitiveness, and the EU’s bargaining power on the international stage.

National competent authorities and member state authorities play a critical role in ensuring supply chain resilience by coordinating, overseeing, and implementing pharmaceutical legislation and policy across the EU.

The COVID-19 pandemic exposed significant vulnerabilities in the EU’s life sciences and pharmaceutical supply chain, prompting the European Commission to propose stronger obligations for marketing authorization holders to notify potential shortages of medicines. The EU aims to create a robust and resilient supply chain capable of meeting its needs in crisis situations through its pharmaceutical strategy, which represents a once-in-a-generation opportunity to strengthen patient safety and improve the resilience of medicine supply chains.

5. Environmental and lifecycle considerations

Environmental risk is becoming more material within the EU pharmaceutical framework. Updated rules require environmental risk assessments for marketing authorization applications, with added scrutiny for certain products such as antimicrobials and medicines involving GMOs.

For early-stage companies, this reinforces the need to think ahead about:

• manufacturing footprint
• packaging and logistics implications
• documentation requirements
• lifecycle planning beyond initial approval

Environmental sustainability and overall sustainability are now key considerations, with the EU reform aiming to reduce the environmental impact of medicines and align with broader EU environmental initiatives.

Integrating these elements early can reduce downstream friction and improve program resilience.

Public procurement is increasingly used as a strategic tool to support environmental and lifecycle goals, stimulating innovation and adoption of sustainable solutions in the pharmaceutical sector.

Ensuring access to high-quality medicines and affordable therapies is central to the reform, which also aims to make sure all patients benefit from safe, effective, and environmentally responsible medicines.

When to build your early stage EU strategy

The best time is usually earlier than most teams think.

You should start now if:

• you are planning first-in-human or early clinical development
• you expect Europe to be part of your value-creation story
• you are preparing for investor, board, or partner discussions
• you want to avoid rework in regulatory or clinical planning
• you need a practical EU pharma strategy for 2026 and beyond

Building your early stage strategy now is crucial to align with the EU’s push for a future proof regulatory framework that supports innovation, leverages new technologies, and ensures sustainability. Additionally, as of early 2026, the FAST-EU initiatives will be piloted to reduce clinical trial authorization times to approximately 70 days, making early planning even more important.

The cost of delayed planning is rarely visible at first. It appears later as slower approvals, weaker evidence packages, country rollout friction, and reduced strategic flexibility.

Build your European roadmap with AzurBio

If your team is evaluating how to expand into Europe, AzurBio can help you create a pragmatic, leadership-ready plan tailored to your asset, timeline, and growth objectives. Our approach ensures your early-stage strategy for EU pharmaceuticals is aligned with the latest European Commission proposal for pharmaceutical reform, while proactively addressing the root causes of supply chain vulnerabilities.